Skip to main content
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

4-Methylmethylphenidate

4-Methylmethylphenidate molecule structure4-Methylmethylphenidate molecule structure
Psychoactive Class
Stimulant
Chemical Class
Phenidate

4-Methylmethylphenidate is a stimulant research chemical structurally related to methylphenidate. It appeared briefly on the market in mid-2015 following bans on ethylphenidate and other phenidates. The substance is reported to be slightly less potent than methylphenidate, with relatively low efficacy at blocking dopamine reuptake despite high binding affinity. It has been described as producing functional stimulation with limited recreational effects and was investigated as a potential substitute treatment for stimulant abuse.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~10 mg
Light10-20 mg
Moderate20-45 mg
Strong45-70 mg
Heavy70+ mg

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

4-Methylmethylphenidate produces a predominantly functional stimulation reminiscent of ethylphenidate, with wakefulness, alertness, and increased energy as its core features. Its recreational character is inconsistent between users: many describe the experience as flat or lacking a rewarding edge, while a minority report euphoria and a distinctly recreational quality at higher doses. As a methylphenidate analogue, its overall profile aligns with that of the substituted phenidate stimulants rather than the entactogens or classical psychedelics.

Physical

Physical effects follow a standard stimulant pattern: increased energy, decreased need for sleep, appetite suppression, sweating, and bruxism. Itchiness, disturbed sleep patterns, and weight loss with repeated use have also been reported.

Stimulation

Uncomfortable

Cognitive

The headspace is stimulating and outwardly directed, with increased sociability, talkativeness, and mood lift reported alongside heightened alertness. Negative shifts in emotional tone, including moodiness, irritability, and aggressiveness, are also reported.

Emotional

Emotional effects are variable, ranging from mood lift and euphoria to irritability and moodiness.

Enhancements

Increased libido

Visual

Visual effects are not characteristic of ordinary use, though hallucinations have been reported.

Auditory

Auditory hallucinations have been reported.

Auditory hallucinations

Pharmacology

Pharmacodynamics

4-Methylmethylphenidate (4-MeTMP) is a stimulant structurally related to methylphenidate that acts on the dopamine transporter. It exhibits high binding affinity at the dopamine transporter but relatively low efficacy at blocking dopamine reuptake, making it slightly less potent than methylphenidate as a dopamine reuptake inhibitor.

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Addiction & Dependence

Psychological

Low

Classified as habit-forming. Its relatively low efficacy at blocking dopamine reuptake despite high binding affinity led to its investigation as a possible substitute drug for treatment of stimulant abuse, suggesting potentially lower reinforcing effects compared to other stimulants.

Psychosis Risk

Visual and auditory hallucinations are listed among possible effects.

History & Culture

4-Methylmethylphenidate emerged on the designer stimulant market in mid-2015, appearing shortly after regulatory actions in the United Kingdom restricted ethylphenidate and other phenidate compounds. Its commercial availability as an unscheduled research chemical proved exceptionally brief, lasting…

Legality

By Country

Illegal2
United States flagUnited StatesIllegal (analog/blanket ban)
United Kingdom flagUnited KingdomIllegal

References

Citations

  1. Misuse of Drugs Act 1971 — Schedule 2: Controlled Drugs (latest available revised version). legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/schedule/21
  2. The Misuse of Drugs Act 1971 (Amendment) Order 2017 (S.I. 2017/634). legislation.gov.uk (n.d.). https://www.legislation.gov.uk/uksi/2017/634/made1
  3. The Misuse of Drugs Act 1971 (Temporary Class Drug) (No. 2) Order 2015 (S.I. 2015/1396). legislation.gov.uk (n.d.). https://www.legislation.gov.uk/uksi/2015/1396/made1
  4. The Misuse of Drugs Act 1971 (Temporary Class Drug) Order 2016 (S.I. 2016/650). legislation.gov.uk (n.d.). https://www.legislation.gov.uk/uksi/2016/650/made1
  5. Misuse of Drugs Act 1971 — Section 5: Restriction of possession of controlled drugs. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/section/51
  6. Electronic Code of Federal Regulations, Title 21, § 1308.12 — Schedule II (September 1, 2026 text). ecfr.gov (n.d.). https://www.ecfr.gov/api/renderer/v1/content/enhanced/2026-09-01/title-21?part=1308&section=1308.121
  7. Electronic Code of Federal Regulations, Title 21, § 1308.11 — Schedule I (September 1, 2026 text). ecfr.gov (n.d.). https://www.ecfr.gov/api/renderer/v1/content/enhanced/2026-09-01/title-21?part=1308&section=1308.111
  8. Electronic Code of Federal Regulations, Title 21, § 1300.01 — Definitions relating to controlled substances (September 1, 2026 text). ecfr.gov (n.d.). https://www.ecfr.gov/api/renderer/v1/content/enhanced/2026-09-01/title-21?part=1300&section=1300.011
  9. Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I, Final Rule, 89 FR 84281. federalregister.gov (n.d.). https://www.federalregister.gov/documents/full_text/xml/2024/10/22/2024-24083.xml1
  10. DEA Controlled Substances — Alphabetical Order (27 August 2026). deadiversion.usdoj.gov (n.d.). https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf1

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 4-Methylmethylphenidate article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.